Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL782399 | 0.93 | MEN1 (0.31) | TDP1MEN1NPC1RAB9AKMT2A | |
| SCHEMBL1966612 | 0.82 | ALDH1A1 (0.37) | HDAC6HDAC1HDAC2TDP1RAB9A | |
| SCHEMBL6534709 | 0.82 | HDAC6 (0.33) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL1742305 | 0.80 | AKT1 (0.39) | HDAC6HDAC1HDAC2CASRNR1D1 | |
| SCHEMBL13110654 | 0.78 | CA14 (0.34) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL9893327 | 0.77 | PHF8 (0.39) | HDAC6HDAC1HDAC2TDP1CASR | |
| SCHEMBL15143768 | 0.77 | HDAC6 (0.34) | HDAC6HDAC1HDAC2TDP1CASR | |
| SCHEMBL28409176 | 0.77 | CA14 (0.41) | CA14HDAC6HDAC1HDAC2CASR | |
| SCHEMBL7176207 | 0.76 | DGAT1 (0.34) | CA14HDAC6HDAC1HDAC2TDP1 | |
| SCHEMBL19511467 | 0.76 | L3MBTL1 (0.35) | CA14CASRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070856-A1 | CROSS-LINKING AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2012-03-22 | — | — | US | disclosed |
| US-20120070856-A1 | CROSS-LINKING AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2012-03-22 | — | — | US | disclosed |
| US-20120070856-A1 | CROSS-LINKING AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | 2012-03-22 | — | — | US | disclosed |
| WO-2010100238-A1 | CROSS-LINKING AGENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-09-10 | — | — | WO | disclosed |
| EP-2226314-A1 | Cross-linking agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- (FR) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070856-A1 | CROSS-LINKING AGENTS | ORC3, TXN, PROC | CA14 3490/4885HDAC6 2616/4885HDAC1 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.